Diplomat Specialty Pharmacy Hires National Accounts Director To Expand Kidney Diseas...( SWARTZ CREEK Mich. April 8 2008 /...),Health

SWARTZ CREEK, Mich., April 8, 2008 /PRNewswire/ -- Diplomat Specialty Pharmacy today announced Mike Maynard has joined the company as Director of National Accounts. Maynard reports directly to Dr. Atheer Kaddis, Vice President of Managed Markets.

Maynard is responsible for the development and national expansion of Diplomat's disease management programs, focusing initially on chronic kidney disease, dialysis, and renal transplant. Diplomat's disease management programs, through direct patient contact and coordination with physicians, improve access, tolerance, and compliance to appropriate medication therapy resulting in improved patient outcomes.

"Diplomat Specialty Pharmacy is very excited to welcome Mike Maynard to our team," said Kaddis. "He will lead our efforts in working with providers, employer groups and managed care organizations to further expand our best in class disease management programs focusing on chronic kidney disease, dialysis, and renal transplant. Mike will help Diplomat become a national leader in caring for patients with kidney disease."

"After spending many years in the renal marketplace, I am very excited to join the team at Diplomat Specialty Pharmacy," said Maynard. "Disease Management programs and initiatives can stem progression of disease, improve medication adherence, control costs and improve quality of life. Diplomat's CKD Navigator Program, as well as the Dialysis and Transplant Programs, are the most comprehensive and innovative programs available. I look forward to being a part of the great things that are happening at Diplomat Specialty Pharmacy."

Maynard's fifteen years as an executive in the pharmaceutical industry include extensive experience in sales, sales management and training, and Regional and National Account Management. Immediately before joining Diplomat Specialty Pharmacy, he served as an Integrated Delivery Network/Renal Account Manager with Roche Pharmaceuticals. In addition, he h
'/>"/>